At a glance
- Originator Pharmacia Corporation
- Class Anti-ischaemics
- Mechanism of Action Fibroblast growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 30 Jun 1997 New profile
- 30 Jun 1997 Preclinical development for Ischaemic heart disorders in USA (Unknown route)